Skip to main navigation Skip to search Skip to main content

NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)

  • Mairéad Geraldine McNamara
  • , Lipika Goyal
  • , Mark Doherty
  • , Christoph Springfeld
  • , David Cosgrove
  • , Katrin Marie Sjoquist
  • , Joon Oh Park
  • , Helena Verdaguer
  • , Chiara Braconi
  • , Paul J. Ross
  • , Aimery De Gramont
  • , John Raymond Zalcberg
  • , Daniel H. Palmer
  • , Juan W. Valle
  • , Jennifer J. Knox
  • University of Manchester
  • Massachusetts General Hospital
  • University of Toronto
  • Heidelberg University 
  • Johns Hopkins University
  • The University of Sydney
  • Vall d'Hebron Institute of Oncology
  • Beatson Oncology Centre
  • Guy's and St Thomas' NHS Foundation Trust
  • Franco-British Institute
  • Monash University
  • University of Liverpool
  • Princess Margaret Cancer Centre

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science